Overall, the U2AF1 mutation is stable during the disease progression of myeloid tumors and may be one of the potential biomarkers for risk stratification and monitoring therapy response in patients with myeloid malignancies, especially MDS [27]. This evidence concerns the gene U2AF1 and myelodysplastic syndrome.